MedTrace Logo

DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury

NCT02110303 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2025-11-18

No results posted yet for this study

Summary

Heart attacks are most commonly caused by rupture of fatty deposits (plaques) within the wall of heart blood vessels. It appears that this process can also frequently occur without causing any symptoms and these events likely explain the development of narrowing within the heart arteries which can subsequently produce symptoms of angina (chest pain).

Previous research has shown a specialised scanner known as a PET (positron emission tomography) scan can identify these recently ruptured plaques in patients without symptoms of a heart attack and these patients have changes on a blood test (troponin) which suggest that they are at higher risk of having a heart attack in the future. This study aims to identify these patients using the PET scan and then see if the markers of increased heart attack risk can be reduced by the use of a blood thinning medication (ticagrelor) which is already a well recognised treatment for people who have suffered a recent heart attack.

Conditions

Interventions

DRUG

Ticagrelor

oral, 90mg tablets, twice daily, 12 month duration

DRUG

Placebo

Oral tablet (identical to ticagrelor), twice daily, 12 month duration

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • David E. Newby, PhD · University of Edinburgh

  • Philip D. Adamson, MBChB · University of Edinburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2017-05-26
Completion
2018-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02110303 on ClinicalTrials.gov